Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

This study is testing a new radioactive drug called 225Ac-LNC1011 in men with advanced prostate cancer that has spread and no longer responds to hormone therapy (called metastatic castration-resistant prostate cancer, or mCRPC). The drug targets a protein called PSMA found on prostate cancer cells and delivers radiation directly to the tumor. **You may be eligible if...** - You have mCRPC — prostate cancer that has spread despite having very low testosterone levels - Your PSA level has risen at least twice, or your cancer has shown new lesions on imaging - You have received prior hormone therapy (like enzalutamide or abiraterone) and at least one chemotherapy (taxane-based) - Your PSMA PET scan shows positive uptake on cancer lesions - You are in reasonably good physical condition (ECOG 0–2) **You may NOT be eligible if...** - Your cancer does not show PSMA expression on a PET scan - You have active serious infections or significant organ dysfunction - You have had prior PSMA-targeted radioligand therapy - You have brain metastases - Your bone marrow function is insufficient Talk to your doctor to see if this trial is right for you.